Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve.
Tetsu TomonariJoji TaniYasushi SatoHironori TanakaTakahiro TanakaTatsuya TaniguchiMorishita AsahiroKoichi OkamotoMasahiro SogabeHiroshi MiyamotoNaoki MugurumaTsutomu MasakiTetsuji TakayamaPublished in: Cancer medicine (2022)
In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a.